Come up with a name for your new list and we'll add to it:
Labrys Biologics was acquired by
Teva Pharmaceuticals on July 21, 2014.
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on the preventive treatment of migraine. Labrys' lead candidate, LBR-101 (formerly RN-307), is an anti-C…